Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase I…
| Métrica | PHIL.MI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | 80.4% | -34.4% | +114.8% |
| Net Margin | 71.8% | -32.5% | +104.2% |
| FCF Margin | 82.7% | -12.6% | +95.2% |
| ROE | 61.4% | -39.2% | +100.6% |
| ROA | 52.5% | -30.9% | +83.5% |
| Current Ratio | 7.76 | 2.73 | +5.03 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 52.5% | — |
| ✓Flujo de caja operativo positivo | €268M | €41M |
| ✓Rentabilidad sobre activos al alza | 52.5% | 26.9% |
| ✓Caja operativa/activos supera al ROA | 61.3% | ROA 52.5% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 7.76 | 7.95 |
| ✓Sin aumentar el nº de acciones | 40M | 40M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.73 | 0.46 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 82.7% |
| ✓ROCE > 10 % | 66.7% |
| ✗Reinversión (I+D + capex) > 3 % de ventas | 1.1% |
PHILOGEN S.P.A. cotiza a 21.65 EUR y tiene una capitalización bursátil de €871M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud